… the current state of late-stage development of active cancer immunotherapies. Based on the
composite experience from these recent phase III studies, we suggest strategies to aid future …

… for colon and rectal cancer patients. In the 1985 analysis, all patients were … of immunotherapy
is limited to patients with colon cancer. There is no perceived benefit in rectal cancer …

… a randomized, double-blind, placebo-controlled phase II trial of adjuvant MAGE-A3
immunotherapeutic (2:1 randomization … resected MAGE-A3–positive TNM stage 18 IB or II NSCLC. …

… Colon cancer is … immunotherapy (ASI) with an autologous tumour cell-BCG vaccine with
surgical resection was more beneficial than resection alone in stage II and III colon cancer. …

… In a phase I study that included patients with mRCC, … the results of a randomized phase II
trial that evaluated three doses of … immunotherapy in mRCC. There are a number of ongoing …

… immunotherapeutic agents may differ regarding presence and timing of delayed separation,
randomized phase II trials may improve the ability to plan for definitive phase III trials. …

… to evaluate PROSTVAC-VF in a randomized, controlled, and blinded … randomized phase
II trial reported here was originated under industrial sponsorship with a collaborative research …

… Talimogene laherparepvec is an oncolytic immunotherapy approved in the US, Europe, …
of OPTiM, a randomized open-label phase III trial in patients with unresectable stage IIIB–…

… Immunotherapy is a growing field of treatment for cancer, and over 100 clinical … results of
the phase I trial, we have carried out a randomized phase II/III clinical trial using elpamotide for …

… safety of immunotherapy in large-scale samples. We performed a meta-analysis of 7 phase
III randomized trials and 3 phase II trials comparing immunotherapy to placebo in mCRPC. …